S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Economic and National Security Threats Create Lithium Bonanza (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Economic and National Security Threats Create Lithium Bonanza (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Economic and National Security Threats Create Lithium Bonanza (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
The "Trojan Horse" Hiding Inside Of Biden's $2 Trillion Infrastructure Bill. (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Economic and National Security Threats Create Lithium Bonanza (Ad)
NASDAQ:XFOR

X4 Pharmaceuticals - XFOR Stock Forecast, Price & News

$1.17
0.00 (0.00%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.14
$1.30
50-Day Range
$0.88
$1.30
52-Week Range
$0.86
$6.21
Volume
379,425 shs
Average Volume
302,125 shs
Market Capitalization
$36.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.10

X4 Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
592.3% Upside
$8.10 Price Target
Short Interest
Healthy
3.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.41mentions of X4 Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$7,613 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.91) to ($1.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

79th out of 1,098 stocks

Biological Products, Except Diagnostic Industry

11th out of 174 stocks

XFOR stock logo

About X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on XFOR. B. Riley reduced their price objective on X4 Pharmaceuticals from $10.00 to $7.00 and set a "buy" rating for the company in a research report on Thursday, May 19th. HC Wainwright reduced their price objective on X4 Pharmaceuticals from $8.50 to $3.50 in a research report on Friday.

X4 Pharmaceuticals Stock Performance

Shares of NASDAQ:XFOR traded down $0.01 on Tuesday, reaching $1.17. The company had a trading volume of 3,401 shares, compared to its average volume of 221,188. X4 Pharmaceuticals has a twelve month low of $0.86 and a twelve month high of $6.21. The stock has a 50-day moving average price of $1.14 and a 200 day moving average price of $1.45. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.73 and a quick ratio of 4.73.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.10). During the same period in the prior year, the business earned ($1.30) earnings per share. On average, equities research analysts predict that X4 Pharmaceuticals will post -1.91 EPS for the current fiscal year.

Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Stock News Headlines

X4 Pharmaceuticals Misses Q1 EPS by 11c
X4 Pharmaceuticals's Earnings Outlook
Recap: X4 Pharmaceuticals Q4 Earnings
See More Headlines
Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Company Calendar

Last Earnings
5/12/2022
Today
8/10/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XFOR
Fax
N/A
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.10
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.50
Forecasted Upside/Downside
+592.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-88,700,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3 million
Book Value
$2.61 per share

Miscellaneous

Free Float
29,881,000
Market Cap
$36.06 million
Optionable
Not Optionable
Beta
0.86

Key Executives














XFOR Stock - Frequently Asked Questions

Should I buy or sell X4 Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XFOR shares.
View XFOR analyst ratings
or view top-rated stocks.

What is X4 Pharmaceuticals' stock price forecast for 2022?

3 equities research analysts have issued 1-year price targets for X4 Pharmaceuticals' shares. Their XFOR share price forecasts range from $3.50 to $10.00. On average, they anticipate the company's share price to reach $8.10 in the next year. This suggests a possible upside of 592.3% from the stock's current price.
View analysts price targets for XFOR
or view top-rated stocks among Wall Street analysts.

How has X4 Pharmaceuticals' stock performed in 2022?

X4 Pharmaceuticals' stock was trading at $2.29 at the beginning of 2022. Since then, XFOR stock has decreased by 48.9% and is now trading at $1.17.
View the best growth stocks for 2022 here
.

When is X4 Pharmaceuticals' next earnings date?

X4 Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our XFOR earnings forecast
.

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) released its quarterly earnings results on Thursday, May, 12th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $0.10. During the same quarter in the prior year, the company posted ($1.30) earnings per share.

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

What is X4 Pharmaceuticals' stock symbol?

X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is X4 Pharmaceuticals' stock price today?

One share of XFOR stock can currently be purchased for approximately $1.17.

How much money does X4 Pharmaceuticals make?

X4 Pharmaceuticals (NASDAQ:XFOR) has a market capitalization of $36.06 million and generates $3 million in revenue each year. The company earns $-88,700,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

How many employees does X4 Pharmaceuticals have?

X4 Pharmaceuticals employs 83 workers across the globe.

How can I contact X4 Pharmaceuticals?

X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The official website for the company is www.x4pharma.com. The company can be reached via phone at (857) 529-8300 or via email at ir@arsanis.com.

This page (NASDAQ:XFOR) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.